IntraBio
General Inquiries
Taylor Fields, Senior Vice President
tfields@intrabio.com | intrabio.com
This page is dedicated to news and information about IntraBio’s therapies for use in Niemann-Pick Disease Type C (NPC). Information is released as it becomes available.
CLINICALTRIALS.GOV ABOUT INTRABIO GLOSSARY OF TERMS .
- Acetyl-L-leucine for Niemann-Pick Type C – A Multi-national, Rater-blinded Phase II Trial
Latest News
.
IntraBio Reports Further Detail on Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C. Click here for complete announcement.
10/19/2020 jjb
IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C. Click here for complete Announcement.
09/30/2020 jjb
IntraBio Receives Fast Track Designation from FDA for IB1001 Treatment of NPC. Click here for complete Announcement.
03/25/2020 jjb
IntraBio Announces Extension Phase for NPC Accepted in the United States. Click here for complete Announcement.
03/05/2020 jjb
IntraBio Completes NPC Clinical Trial Enrollment. Click here for complete announcement.
01/17/2020 jjb
IntraBio IB1001-201 Clinical Trial for NPC Reaches 2/3 of their Recruitment Goal. Click here for complete announcement.
11/13/2019 jjb
IntraBio Clinical Trial IB1001-201 Open for US Recruitment at Mayo Clinic. Click here for complete announcement.
09/04/2019 jjb
IntraBio is developing a number of small-molecule drug candidates that have broad applicability to rare and common neurological disorders, genetic, and inflammatory diseases. Their current lead drug candidate, IB1001, is initially being developed to treat three rare, genetic diseases where there are extremely high unmet medical needs: Niemann-Pick disease type C, GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease), and Ataxia-Telangiectasia (A-T; an inherited Cerebellar Ataxia). Click the link below for additional information.
Click here for IB1000 Series development history.
05/31/2019 jjb
NNPDF Industry Update Webinar Series featuring IntraBio, Inc. Click here for recording.
04/25/2019 jjb
IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of NPC. Click here for complete announcement.
03/11/2019 jjb
IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of NPC. Click here for complete announcement.
02/13/2019 jjb
IntraBio Receives Niemann-Pick Disease Orphan Drug Designation from the FDA for IB1000 Series. Click here for complete announcement.
11/26/2018 jjb